Literature DB >> 9822798

Growth hormone-dependent regulation of pituitary GH secretagogue receptor (GHS-R) mRNA levels in the spontaneous dwarf Rat.

J Kamegai1, I Wakabayashi, K Miyamoto, T G Unterman, R D Kineman, L A Frohman.   

Abstract

Growth hormone secretagogues (GHSs) are synthetic peptidyl and nonpeptidyl compounds that are believed to stimulate the release of GH by a direct effect on the pituitary somatotrope and by stimulation of growth hormone-releasing hormone (GHRH) release and the suppression of somatostatin (SRIH) tone. Recently, the receptor for these pharmacologic agents was cloned and its expression localized to the pituitary and hypothalamus. The elucidation of an unique GHS receptor (GHS-R) suggests there is a yet to be identified endogenous ligand which could exert an important role in regulation of GH secretion. It is clearly established that GH acts to regulate its own production by feeding back at the level of the hypothalamus to downregulate GHRH and upregulate SRIH synthesis and by induction of IGF-I, which acts at the pituitary to block somatotrope responsiveness to GHRH. If the endogenous GHS/GHS-R signaling system is important in regulating GH release, it might be reasoned that changes in circulating GH concentrations would also directly or indirectly (via generation of IGF-I) modify GHS-R production. To test this hypothesis we used RT-PCR to examined pituitary and hypothalamic GHS-R mRNA levels in the spontaneous dwarf rat (SDR), an animal model characterized by the absence of GH due to a point mutation in the GH gene. In the absence of GH feedback regulation, SDR pituitary GHS-R mRNA levels were 385 +/- 61% greater (p < 0.01) than those observed in normal controls while SDR hypothalamic GHS-R mRNA levels were not significantly different from those in normal rats. Three-day subcutaneous infusion of rat GH by osmotic pump reduced SDR pituitary GHS-R mRNA levels to 55 +/- 9% of vehicle-treated controls (p < 0.05) but did not significantly alter hypothalamic GHS-R mRNA levels. To test if the changes in GHS-R mRNA levels observed following GH treatment were due to elevation of circulating IGF-I concentrations, SDRs were infused with recombinant human IGF-I. Replacement of IGF-I did not significantly alter either pituitary or hypothalamic GHS-R mRNA levels, indicating that GH acts independent of circulating IGF-I to regulate pituitary GHS-R expression in the SDR model.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9822798     DOI: 10.1159/000054379

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  11 in total

1.  Sleep disturbances, daytime sleepiness, and quality of life in adults with growth hormone deficiency.

Authors:  Georges Copinschi; Arlet Nedeltcheva; Rachel Leproult; Lisa L Morselli; Karine Spiegel; Enio Martino; Jean-Jacques Legros; Roy E Weiss; Jean Mockel; Eve Van Cauter
Journal:  J Clin Endocrinol Metab       Date:  2010-03-23       Impact factor: 5.958

2.  Effect of gsp oncogene on somatostatin receptor subtype 1 and 2 mRNA levels in GHRH-responsive GH3 cells.

Authors:  Eunhee Kim; Sookjin Sohn; Mina Lee; Cheolyoung Park; Jeechang Jung; Seungjoon Park
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 3.  Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.

Authors:  J D Veldhuis; W S Evans; C Y Bowers; S Anderson
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

4.  Differential regulation of GHRH-receptor and GHS-receptor expression by long-term in vitro treatment of ovine pituitary cells with GHRP-2 and GHRH.

Authors:  Sang-Gun Roh; Maria Doconto; Dan Dan Feng; Chen Chen
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

5.  Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity.

Authors:  Yujin Shuto; Tamotsu Shibasaki; Asuka Otagiri; Hideki Kuriyama; Hisayuki Ohata; Hideki Tamura; Jun Kamegai; Hitoshi Sugihara; Shinichi Oikawa; Ichiji Wakabayashi
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

6.  Role of Glucocorticoids in Fasting-induced Changes in Hypothalamic and Pituitary Components of the Growth Hormone (GH)-axis.

Authors:  Eunhee Kim; Sanghee Seo; Hyunju Chung; Seungjoon Park
Journal:  Korean J Physiol Pharmacol       Date:  2008-10-31       Impact factor: 2.016

7.  Feeding behavior during long-term hexarelin administration in young and old rats.

Authors:  E Bresciani; N Pitsikas; L Tamiazzo; M Luoni; I Bulgarelli; D Cocchi; V Locatelli; A Torsello
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

Review 8.  Growth hormone secretagogues and hypothalamic networks.

Authors:  M T Bluet-Pajot; V Tolle; P Zizzari; C Robert; C Hammond; V Mitchell; J C Beauvillain; C Viollet; J Epelbaum; C Kordon
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.925

9.  Ghrelin receptors in non-Mammalian vertebrates.

Authors:  Hiroyuki Kaiya; Kenji Kangawa; Mikiya Miyazato
Journal:  Front Endocrinol (Lausanne)       Date:  2013-07-17       Impact factor: 5.555

10.  Ghrelin accelerates the growth and osteogenic differentiation of rabbit mesenchymal stem cells through the ERK1/2 pathway.

Authors:  Nan Ye; Dianming Jiang
Journal:  BMC Biotechnol       Date:  2015-06-09       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.